ENLV Stock Summary and Trading Ideas (Enlivex Ltd. - | NASDAQ:ENLV)

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Enlivex Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of September 8, 2026, ENLV stock price climbed to $1.11 with 185,172 million shares trading.

ENLV has a beta of 0.29, meaning it tends to be less sensitive to market movements. ENLV has a correlation of 0.00 to the broad based SPY ETF.

ENLV has a market cap of $19.41 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ENLV traded as high as $68.85 and as low as $1.02.

ENLV has underperformed the market in the last year with a price return of -93.1% while the SPY ETF gained +19.2%. ENLV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -90.6% and -24.5%, respectively, while the SPY returned +1.4% and 0.0%, respectively.

ENLV support price is $1.01 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.